APA (7th ed.) Citation

L, T., N, R., W, A., A, B. d. l. P., A, L. H., A, J., . . . M, Q. (2023). Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia. European journal of endocrinology, 188(1), . https://doi.org/10.1093/ejendo/lvac006

Chicago Style (17th ed.) Citation

L, Tschaidse, et al. "Modified-release Hydrocortisone Is Associated with Lower Plasma Renin Activity in Patients with Salt-wasting Congenital Adrenal Hyperplasia." European Journal of Endocrinology 188, no. 1 (2023). https://doi.org/10.1093/ejendo/lvac006.

MLA (9th ed.) Citation

L, Tschaidse, et al. "Modified-release Hydrocortisone Is Associated with Lower Plasma Renin Activity in Patients with Salt-wasting Congenital Adrenal Hyperplasia." European Journal of Endocrinology, vol. 188, no. 1, 2023, https://doi.org/10.1093/ejendo/lvac006.